PointState Capital’s Teva Pharmaceuticals TEVA Stock Holding History

PointState Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,672,100	Closed	-$115M	–	66
2025 Q4	$115M	Hold	3,672,100	–	–	1.69%	28
2025 Q3	$74.2M	Hold	3,672,100	–	–	1.11%	32
2025 Q2	$61.5M	Hold	3,672,100	–	–	0.94%	31
2025 Q1	$56.4M	Buy	3,672,100 +1,172,100	+47%	+$20.9M	0.82%	35
2024 Q4	$55.1M	Hold	2,500,000	–	–	1%	30
2024 Q3	$45M	Hold	2,500,000	–	–	0.82%	28
2024 Q2	$40.6M	Buy	+2,500,000	New	+$38.5M	0.88%	36
2016 Q4	–	Sell	-36,500	Closed	-$1.68M	–	161
2016 Q3	$1.68M	Buy	+36,500	New	+$1.9M	0.02%	136

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

PointState Capital's TEVA Position: Q2 2026 in Review

PointState Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 1,973,782 shares — an estimated $59.5M sold.

PointState Capital first reported a position in TEVA in Q4 2013 and held it in 22 quarters. The position peaked at $751M in Q2 2016. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

PointState Capital reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
PointState Capital sold 1,973,782 Teva Pharmaceuticals shares in Q2 2026, an estimated $59.5M.
PointState Capital first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 22 quarters.
PointState Capital's Teva Pharmaceuticals position peaked at $751M in Q2 2016.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on PointState Capital's 13F filing for Q2 2026, filed 14 Aug 2026.